<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179396</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-107</org_study_id>
    <nct_id>NCT04179396</nct_id>
  </id_info>
  <brief_title>Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)</brief_title>
  <acronym>RAMP</acronym>
  <official_title>A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib&#xD;
      in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant&#xD;
      Prostate Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the PK of rucaparib in combination with other anticancer agents for mCRPC.</measure>
    <time_frame>2 years to complete</time_frame>
    <description>Cmin of rucaparib and its metabolite.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the number of reported treatment-related AEs/SAEs in combination with other anticancer agents for mCRPC.</measure>
    <time_frame>2 years to compete</time_frame>
    <description>Number of participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) as assessed by CTCAE v5.0 as a measure of safety and tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the preliminary overall response rate (ORR) of rucaparib in combination with other anticancer agents for mCRPC.</measure>
    <time_frame>2 years to compete</time_frame>
    <description>Preliminary overall response rate (ORR) defined as the proportion of patients with a best overall response of CR or PR according to modified RECIST 1.1 and PCWG3 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Oral rucaparib and enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Oral rucaparib and abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Oral rucaparib will be administered twice daily</description>
    <arm_group_label>Arm A: Oral rucaparib and enzalutamide</arm_group_label>
    <arm_group_label>Arm B: Oral rucaparib and abiraterone</arm_group_label>
    <other_name>Rubraca</other_name>
    <other_name>CO-338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide will be administered once daily.&#xD;
Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved.</description>
    <arm_group_label>Arm A: Oral rucaparib and enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone will be administered once daily with prednisone</description>
    <arm_group_label>Arm B: Oral rucaparib and abiraterone</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)&#xD;
             approved informed consent form prior to any study-specific evaluation&#xD;
&#xD;
          -  Be ≥18 yrs of age at the time the informed consent form is signed&#xD;
&#xD;
          -  Be either AR-directed therapy-naive or have received 1-2 lines of AR-directed therapy&#xD;
             in the castration-resistant setting.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Have a histologically or cytologically confirmed adenocarcinoma or poorly&#xD;
             differentiated carcinoma of the prostate that is metastatic&#xD;
&#xD;
          -  Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL&#xD;
             (1.73 nM)&#xD;
&#xD;
          -  Have disease progression after initiation of most recent therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active second malignancy, with the exception of curatively treated non melanoma skin&#xD;
             cancer, carcinoma in situ, or superficial bladder cancer&#xD;
&#xD;
          -  Have received greater than 2 previous lines of chemotherapy for mCRPC&#xD;
&#xD;
          -  Prior treatment with any PARP inhibitor&#xD;
&#xD;
          -  Symptomatic and/or untreated central nervous system metastases&#xD;
&#xD;
          -  Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would,&#xD;
             in the opinion of the investigator, interfere with absorption of study drug&#xD;
&#xD;
          -  Spinal cord compression, symptomatic and/or untreated central nervous system (CNS)&#xD;
             metastases or leptomeningeal disease. Patients with asymptomatic previously treated&#xD;
             CNS metastases are eligible provided they have been clinically stable for at least 4&#xD;
             weeks&#xD;
&#xD;
          -  Any clinically significant cardiovascular disease&#xD;
&#xD;
          -  Taking any concomitant medications or herbs that could interfere or interact with the&#xD;
             study drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Piedmont Cancer Institute, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRPC</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>RAMP</keyword>
  <keyword>homologous recombination</keyword>
  <keyword>DNA repair</keyword>
  <keyword>DNA defect</keyword>
  <keyword>DNA anomaly</keyword>
  <keyword>mCRPC</keyword>
  <keyword>enzalutamide</keyword>
  <keyword>abiraterone</keyword>
  <keyword>Zytiga</keyword>
  <keyword>Xtandi</keyword>
  <keyword>ADT</keyword>
  <keyword>AR</keyword>
  <keyword>ARi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

